Literature review · Muscle & strength

CJC-1295 with DAC

Human experiments support prolonged GH and IGF-I signalling from a defined long-acting CJC-1295 analogue. Those endocrine findings do not establish a muscle or strength benefit.

By HeartPep · Reviewed · 2 selected source records

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

At a glance

The selected evidence connects preclinical albumin-binding pharmacology with short controlled human hormone-response trials. It is strongest for the measured endocrine response, rather than a performance outcome.

Identity & scope

The long-acting analogue in these papers contains an albumin-binding modification. Its results must stay separate from no-DAC listings.

Catalogue labels covered: CJC-1295 with DAC.

What the research shows

  • The human trials below measured circulating hormones and drug persistence, rather than athletic performance.

Critical interpretation

A preserved pulse is only part of the hormone profile

The overnight sampling study adds a useful qualification to the phrase preserved pulsatility. Pulse frequency and size did not significantly change, while trough GH rose. A pulsatile pattern can therefore coexist with a higher background concentration. This is evidence about the shape of an endocrine response, not proof that normal physiology has been restored or that a favourable clinical outcome follows. The paper is especially useful when a secondary account presents pulsatility as a complete safety argument. [2]

What the controlled trials can establish

The ascending-exposure trials support a causal effect of the defined long-acting analogue on measured hormone concentrations in healthy adults. Randomisation helps answer that narrow question. It does not supply an unmeasured outcome: strength, functional recovery and treatment of a deficient population would each need appropriate participants and direct endpoints. The reported persistence also belongs to the modified study molecule. It is not a generic property of every product using the CJC name. [1]

Limitations & uncertainties

  • Short follow-up cannot resolve long-term safety. A catalogue name does not establish the studied formulation or an equivalent delivery profile.

Open research questions

  • Which exact sequence and albumin-binding modification are documented for the material?
  • Is the proposed experimental endpoint a hormone marker, or an independently measured functional outcome?

Selected papers & source records

Download bibliography
Human studyNamed compoundAbstract / record checked

1. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (opens in a new tab)

Teichman SL, Neale A, Lawrence B, et al. (2006). Journal of Clinical Endocrinology & Metabolism. DOI: 10.1210/jc.2005-1536 (opens in a new tab) · PMID 16352683

Design & population
Two randomized, double-blind, placebo-controlled ascending-exposure trials, lasting 28 and 49 days, in healthy adults aged 21–61.
What the study found
The defined long-acting analogue produced sustained increases in GH and IGF-I. Its estimated half-life was 5.8–8.1 days.
Limits on interpretation
Hormone concentrations and short-term tolerability were assessed. These trials did not establish improved strength, muscle performance or long-term safety.
Human studyNamed compoundAbstract / record checked

2. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog (opens in a new tab)

Ionescu M, Frohman LA. (2006). Journal of Clinical Endocrinology & Metabolism. DOI: 10.1210/jc.2006-1702 (opens in a new tab) · PMID 17018654

Design & population
Healthy men underwent overnight blood sampling before and one week after a defined long-acting CJC-1295 intervention.
What the study found
GH pulses persisted, while trough and mean GH concentrations increased. Pulse frequency and magnitude were not significantly changed.
Limits on interpretation
An endocrine time-course experiment. Preserved pulses do not demonstrate normalisation of a disease state, improved performance or long-term safety.

Search & review scope

Targeted web searches of PubMed-indexed primary research and original journal records. Selected abstracts and citation metadata were checked; full-text sections were consulted for the records explicitly labelled full-text. Retrieved records and targeted notice searches were also checked for visible corrections or retractions.. Checked 9 November 2026.

Selected primary research relevant to the named compound, its molecular specification and the endpoints described below.

Narrative selection, not a systematic review, comprehensive safety assessment or complete retraction audit. PubMed/PMC full-text access was intermittent. An abstract or selected-section review cannot replace appraisal of the complete methods, supplements and underlying data. Absence from this selection does not establish absence of research.

Recorded search terms
  • site.pubmed.ncbi.nlm.nih.gov 16352683 CJC-1295 Teichman
  • site.pubmed.ncbi.nlm.nih.gov CJC-1295 no DAC modified GRF 1-29 trial
  • site.pubmed.ncbi.nlm.nih.gov CJC-1295 pulsatile secretion randomized Teichman 2006
  • "17018654" DOI Ionescu

Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.

Cite this review

HeartPep. CJC-1295 with DAC: literature review. HeartPep literature library. Reviewed 9 November 2026. https://heartpep.com/uk/research/library/cjc-1295-with-dac.

HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

← All reviews and reference notes